-+ 0.00%
-+ 0.00%
-+ 0.00%

Fennec says Phase 2 Japan study shows Pedmark cuts cisplatin-linked hearing loss to 24% in pediatric, AYA patients

PUBT·09/17/2026 11:31:34
Listen to the news
Fennec says Phase 2 Japan study shows Pedmark cuts cisplatin-linked hearing loss to 24% in pediatric, AYA patients
  • Fennec Pharmaceuticals announced detailed Phase 2 STS-J01 results for Pedmark in Japan, presented at the SIOP 2026 annual meeting.
  • Trial showed reduced cisplatin-related hearing loss in pediatric and adolescent or young adult patients with localized, non-metastatic solid tumors.
  • Data supported no apparent reduction in tumor response with delayed Pedmark dosing, addressing a key adoption concern for clinicians.
  • Safety profile aligned with prior experience for Pedmark; no serious adverse event was attributed to the drug.
  • Fennec is pursuing Japanese registration, signaling a potential new market expansion path for Pedmark.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fennec Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609170730PRIMZONEFULLFEED9828541) on September 17, 2026, and is solely responsible for the information contained therein.